Cargando…
Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a rare vasculopathy, with high morbidity and mortality. The sensitivity of the current european society of cardiology/european respiratory society (ESC/ERS) risk assessment strategy may be improved by the addition of biomarkers related to PAH pathophysiology....
Autores principales: | Arvidsson, Mattias, Ahmed, Abdulla, Säleby, Joanna, Ahmed, Salaheldin, Hesselstrand, Roger, Rådegran, Göran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368940/ https://www.ncbi.nlm.nih.gov/pubmed/37502145 http://dx.doi.org/10.1002/pul2.12269 |
Ejemplares similares
-
Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2022) -
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019) -
Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021) -
Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
por: Ahmed, Abdulla, et al.
Publicado: (2021) -
Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)